Skip to Main Content

SINGAPORE — A young immuno-oncology company aims to pitch biomarker data for its lead drug candidate at the American Society of Clinical Oncology meeting in Chicago this summer, spreading the word about its ongoing Phase 3 trials.

Tessa Therapeutics could also send a message to fledgling Asian biotech hubs hoping to replicate the success of centers in other parts of the world.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!